Combined oral contraceptive pill probably leads to higher improvement in MBL (participant assessment) compared with placebo (moderate certainty).
The review found no eligible studies for this question.
Combined oral contraceptive pill probably leads to higher adverse events ‐ Any adverse events (treatment‐emergent) compared with placebo (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Combined oral contraceptive pill may leads to lower treatment success (PBAC < 100 at end of treatment or no requirement… compared with levonorgestrel‐releasing intrauterine system (low certainty).
It is very uncertain whether combined oral contraceptive pill changes satisfaction with treatment compared with levonorgestrel‐releasing intrauterine system (very low certainty).
Multinutrient supplements (oral) showed no clear difference in mortality by end of study compared with control (low certainty).
Multinutrient supplements (oral) may leads to lower participants with complications (e.g. pressure sore, chest… compared with control (low certainty).
It is very uncertain whether multinutrient supplements (oral) changes unfavourable outcome 7 by end of study compared with control (very low certainty).
It is very uncertain whether multinutrient supplements (oral) changes putative side effects of treatment (e.g. vomiting and diarrhoea) compared with control (very low certainty).
Oral alkylating agents ± steroids showed no clear difference in death at final compared with placebo/no treatment/steroids (low certainty).
Oral alkylating agents ± steroids probably leads to lower end‐stage kidney disease at final compared with placebo/no treatment/steroids (moderate certainty).
Oral alkylating agents ± steroids probably leads to higher total remission (complete or partial) at final compared with placebo/no treatment/steroids (moderate certainty).
Oral alkylating agents ± steroids probably leads to higher complete remission at final compared with placebo/no treatment/steroids (moderate certainty).
It is very uncertain whether oral alkylating agents ± steroids changes recurrence of disease (relapse) at final compared with placebo/no treatment/steroids (very low certainty).
Oral alkylating agents ± steroids showed no clear difference in 100% increase in serum creatinine at final compared with placebo/no treatment/steroids (moderate certainty).
Oral alkylating agents ± steroids may leads to higher adverse events ‐ temporary/permanent discontinuation or… compared with placebo/no treatment/steroids (low certainty).
It is very uncertain whether oral alkylating agents ± steroids changes adverse events ‐ infection at 3 years compared with placebo/no treatment/steroids (very low certainty).